NDAORALTABLETPriority Review
Approved
Oct 2001
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
21
Data completeness
4/8 — Partial
Priority Review
VIREAD (tenofovir disoproxil fumarate) by Gilead Sciences. Approved for hiv infection, hepatitis b, hepatitis c and 6 more indications. First approved in 2001.
VIREAD (tenofovir disoproxil fumarate) is an oral nucleotide reverse transcriptase inhibitor approved in 2001 for treating HIV infection and hepatitis B. The drug is also indicated for hepatitis C, hepatitis D, and associated complications including Kaposi's sarcoma, hepatocellular carcinoma, cirrhosis, dyslipidemia, and lipodystrophy. It works by inhibiting viral reverse transcriptase, blocking replication of HIV and hepatitis B virus.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; teams should expect resource optimization and focus on lifecycle extension strategies rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (9)
Worked on VIREAD at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.